On 27 April 2026, the European Commission published the final draft of a CE marking amendment (WTO/TBT notification G/TBT/N/EU/1123), mandating ULPA-grade Microbial Viral Retention (MVR) testing for all industrial air filters exported to the EU — including HEPA and ULPA modules — effective 1 October 2026. This development directly affects manufacturers, exporters, and technical documentation providers in the air filtration supply chain, particularly those supplying cleanroom, pharmaceutical, semiconductor, and critical infrastructure sectors.

Event Overview

The European Commission notified the final draft revision of CE requirements for industrial air filters via the WTO/TBT portal on 27 April 2026 (G/TBT/N/EU/1123). The draft mandates compliance with EN 1822-5:2026 Annex D — specifically the new bacteriophage ΦX174 challenge method for Microbial Viral Retention (MVR) testing — for all HEPA and ULPA modules placed on the EU market from 1 October 2026 onward. Affected products must undergo full type testing and updated technical documentation under this revised standard.

Industries and Supply Chain Roles Affected

Direct Exporters and OEMs

Exporters placing industrial air filters into the EU market will face mandatory re-certification before 1 October 2026. Non-compliant units cannot be legally placed on the market after that date, risking shipment rejection, customs delays, or withdrawal from distribution channels.

Filter Media and Module Manufacturers

Chinese and other non-EU filter media producers supplying HEPA/ULPA modules must now validate performance against the ΦX174 phage challenge — a test more stringent than traditional particle-based efficiency measurements. This requires re-engineering or qualification of existing media formulations and production processes.

Technical Documentation and Certification Service Providers

Notified Bodies and technical documentation support firms must update their assessment protocols to include EN 1822-5:2026 Annex D. Clients relying on legacy test reports or declarations will need to commission new type tests and revise EU Declarations of Conformity accordingly.

What Relevant Enterprises or Practitioners Should Focus On — And How to Respond

Monitor official adoption timelines and national transposition status

The notified draft is not yet law; it remains subject to final approval and publication in the Official Journal of the EU. Enterprises should track whether the regulation enters into force as scheduled on 1 October 2026 or if transitional provisions apply.

Prioritize validation for high-risk product categories

Filters used in sterile manufacturing (e.g., ISO Class 5 cleanrooms), biopharma ventilation, or isolation systems are most likely to fall under strict enforcement scrutiny. Firms should sequence MVR re-testing starting with these priority SKUs.

Distinguish between regulatory signal and operational readiness

While the draft is final, testing capacity for ΦX174 challenge — especially at accredited labs outside the EU — remains limited. Companies should confirm lab availability, lead times, and report acceptance criteria with their Notified Body well in advance.

Update internal technical files and supplier communication protocols

Manufacturers must revise risk assessments, design verification records, and supplier quality agreements to reflect MVR as a mandatory performance parameter. Downstream buyers may request updated test data or co-sign revised declarations — early alignment is advisable.

Editorial Perspective / Industry Observation

Observably, this amendment signals a structural shift in EU regulatory focus: from particulate removal efficiency toward biological barrier performance in critical air handling applications. Analysis shows it is less a sudden enforcement escalation and more a formalization of emerging expectations among EU health and safety authorities — particularly following pandemic-era scrutiny of airborne pathogen control. From an industry perspective, the ΦX174 challenge introduces a standardized, biologically relevant metric previously absent from EN 1822. It is not yet a de facto global benchmark, but its inclusion in CE requirements elevates its relevance for export-oriented suppliers beyond the EU alone.

Current attention should center on implementation feasibility — notably test accessibility, reproducibility across labs, and alignment between EN 1822-5:2026 Annex D and existing ISO or ASTM microbial filtration standards — rather than treating the requirement as fully operationalized.

Conclusion

This CE amendment marks a targeted tightening of conformity obligations for industrial air filtration in the EU — one grounded in enhanced biological performance verification, not broad-spectrum regulatory expansion. It reflects growing emphasis on real-world pathogen interception capability, especially in sensitive environments. At present, it is best understood as a binding regulatory milestone with defined timelines, but whose practical execution hinges on lab capacity, harmonized interpretation, and timely updates to technical documentation systems.

Information Sources

Main source: WTO/TBT Notification G/TBT/N/EU/1123, published by the European Commission on 27 April 2026.
Further observation required: Final publication date in the Official Journal of the EU, national implementation guidance from EU Member States’ market surveillance authorities, and accreditation status of third-party labs offering EN 1822-5:2026 Annex D testing.